Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal ...

26 October 2026 · By · Wire by Fusion42

Published

26 October 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at investingnews.com →

◆ Verified

Fusion42 · 26 October 2026 · Fusion42 review

Mirum Pharmaceuticals announced positive results from Cohort 2 of the PROGRESS study where their drug ATEBRIOZ (zilurgisertib) reduced heterotopic ossification lesion volume and improved joint mobility in pediatric patients aged 6 to under 12 years with fibrodysplasia ossificans progressiva (FOP), with plans to submit for FDA approval to expand the indication to this younger age group in H1 2027.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can now target a younger FOP patient group as FDA approval expansion is imminent; start engaging paediatric specialists and health systems to build early access pathways.

◆ Coverage

1 source · 26 Oct 2026

◆ Related on Wire

◆ Topics

Biotechrare-diseasedrug-approvalpediatricsFOPclinical-trialFDA